Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study

Background/Aim: The median age of subjects in many clinical trials of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor conducted to date has been approximately 60 years. However, it is not uncommon to encounter EGFR gene -positive patients in their 70s or 80s. Based on information obtained from these clinical trials, EGFR gene -positive non -small cell lung cancer (NSCLC) patients are considered to be younger than EGFR-negative patients. In this study, we analyzed clinical data to identify whether this assumption is true. Patients and Methods: We retrospectively reviewed the medical records of NSCLC patients diagnosed in a multicenter clinical practice from 2009 to 2023. Patients included all cases of non -advanced and advanced NSCLC. Results: Information on 2,540 patients, including 605 EGFR gene -positive patients, was collected. The median age of EGFR-positive and EGFRnegative patients was 72 years and 71 years, respectively, and there was no significant difference in the age of patients between these two groups (p=0.7887). The most common age in these two groups was 70 years. Among the EGFR gene subtypes, the frequency of exon 19 deletion decreased with age, whereas that of EGFR L858R increased. Conclusion: Patients in their 70s and 80s with non -small cell lung cancer were relatively frequently EGFR gene -positive. To avoid missing out on treatment opportunities, EGFR gene testing should also be performed on patients in this age group.